Literature DB >> 8442432

Collagen crosslinks and mineral crystallinity in bone of patients with osteogenesis imperfecta.

U Vetter1, M A Weis, M Mörike, E D Eanes, D R Eyre.   

Abstract

In cortical bone samples from patients with osteogenesis imperfecta (OI), the concentrations of hydroxypyridinium cross-linking amino acids in collagen were measured by reversed-phase HPLC and the x-axis crystallinity of the apatite mineral phase was determined by x-ray diffraction. Bone samples from three patients with type I, nine patients with type III, and eight patients with type IV OI were analyzed and compared with human bone from nine controls. The concentration of the two chemical forms of the mature collagen crosslinking amino acids, hydroxylysylpyridinoline (HP) and lysylpyridinoline (LP), and the ratio HP/LP were found to be alike in bone collagen of OI patients and healthy controls. However, the c-axis crystallinity of the apatite was found to be reduced in the type III and IV OI patients compared with controls. Regression analysis of crosslink concentrations and c-axis crystallinity in OI bones did not show any correlation. Therefore, collagen molecules deposited in the extracellular matrix of OI bone appear to fulfill the structural requirements for the action of the enzyme lysyl oxidase, such that a normal concentration of intermolecular crosslinks is formed compared with healthy bone. Consequently, crosslink formation and apatite crystal growth seem to be regulated independently in OI bone.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8442432     DOI: 10.1002/jbmr.5650080203

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  9 in total

1.  Collagen from the osteogenesis imperfecta mouse model (oim) shows reduced resistance against tensile stress.

Authors:  K Misof; W J Landis; K Klaushofer; P Fratzl
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

Review 2.  Unlike bone, cartilage regeneration remains elusive.

Authors:  Daniel J Huey; Jerry C Hu; Kyriacos A Athanasiou
Journal:  Science       Date:  2012-11-16       Impact factor: 47.728

Review 3.  Bone composition: relationship to bone fragility and antiosteoporotic drug effects.

Authors:  Adele L Boskey
Journal:  Bonekey Rep       Date:  2013-12-04

4.  Multiscale modeling of keratin, collagen, elastin and related human diseases: Perspectives from atomistic to coarse-grained molecular dynamics simulations.

Authors:  Jingjie Yeo; GangSeob Jung; Anna Tarakanova; Francisco J Martín-Martínez; Zhao Qin; Yuan Cheng; Yong-Wei Zhang; Markus J Buehler
Journal:  Extreme Mech Lett       Date:  2018-02-24

Review 5.  Osteogenesis imperfecta: from phenotype to genotype and back again.

Authors:  R Smith
Journal:  Int J Exp Pathol       Date:  1994-08       Impact factor: 1.925

6.  Dissecting the phenotypic variability of osteogenesis imperfecta.

Authors:  Nadia Garibaldi; Roberta Besio; Raymond Dalgleish; Simona Villani; Aileen M Barnes; Joan C Marini; Antonella Forlino
Journal:  Dis Model Mech       Date:  2022-05-16       Impact factor: 5.732

7.  Bone mineralization in an osteogenesis imperfecta mouse model studied by small-angle x-ray scattering.

Authors:  P Fratzl; O Paris; K Klaushofer; W J Landis
Journal:  J Clin Invest       Date:  1996-01-15       Impact factor: 14.808

Review 8.  Extracellular matrix mineralization in periodontal tissues: Noncollagenous matrix proteins, enzymes, and relationship to hypophosphatasia and X-linked hypophosphatemia.

Authors:  Marc D McKee; Betty Hoac; William N Addison; Nilana M T Barros; José L Millán; Catherine Chaussain
Journal:  Periodontol 2000       Date:  2013-10       Impact factor: 7.589

9.  Abnormal type I collagen post-translational modification and crosslinking in a cyclophilin B KO mouse model of recessive osteogenesis imperfecta.

Authors:  Wayne A Cabral; Irina Perdivara; MaryAnn Weis; Masahiko Terajima; Angela R Blissett; Weizhong Chang; Joseph E Perosky; Elena N Makareeva; Edward L Mertz; Sergey Leikin; Kenneth B Tomer; Kenneth M Kozloff; David R Eyre; Mitsuo Yamauchi; Joan C Marini
Journal:  PLoS Genet       Date:  2014-06-26       Impact factor: 5.917

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.